Related Experiment Video
Updated: Jun 5, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT
Ecaterina Elena Dumbrava1, Khaoula Ben Haj Frej2, Elad Sharon3
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;
Abstract:
Immune checkpoint blockade targeting the novel targets of the lymphocyte activation gene 3 (LAG3) and the T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) has marked a significant advancement in oncology, offering new therapeutic opportunities to fight diverse malignancies. This review covers the biological basis and clinical application of LAG3 and TIGIT inhibitors, highlighting pivotal trials and therapeutic outcomes. We underscore the use of dual therapy immune checkpoint blockade in enhancing antitumor immunity, particularly in settings where monotherapy has shown limited efficacy. Additionally, we address the emerging challenges such as treatment resistance and adverse effects. We explore the strategic integration of LAG3 and TIGIT blockade within the broader immunotherapy landscape, emphasizing innovative combinations and the quest for predictive biomarkers to optimize patient selection and treatment efficacy.
Insights
New immune checkpoint inhibitors targeting lymphocyte activation gene 3 (LAG3) and T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) offer advanced oncology treatments. Dual therapy shows promise in overcoming monotherapy limitations for diverse cancers.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Immune checkpoint blockade has revolutionized cancer treatment.
- Lymphocyte activation gene 3 (LAG3) and T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) are novel targets for immune modulation.
- Understanding LAG3 and TIGIT pathways is crucial for developing next-generation immunotherapies.
Purpose of the Study:
- To review the biological basis and clinical applications of LAG3 and TIGIT inhibitors.
- To highlight pivotal clinical trials and therapeutic outcomes associated with these novel targets.
- To discuss the potential of dual therapy and combination strategies in cancer treatment.
Main Methods:
- Literature review of preclinical and clinical studies on LAG3 and TIGIT inhibitors.
- Analysis of data from key clinical trials investigating LAG3 and TIGIT blockade.
- Exploration of emerging challenges and future directions in the field.
Main Results:
- LAG3 and TIGIT inhibitors represent significant advancements in oncology.
- Dual immune checkpoint blockade enhances antitumor immunity, especially when monotherapy is insufficient.
- Pivotal trials demonstrate varying therapeutic outcomes across different malignancies.
Conclusions:
- LAG3 and TIGIT blockade offer new therapeutic avenues for diverse cancers.
- Combination therapies and predictive biomarkers are essential for optimizing patient selection and treatment efficacy.
- Addressing treatment resistance and adverse effects is critical for the successful integration of these therapies.
